| | |
ROC coefficients*
|
P value
|
AUC (95% CI)
|
|---|
|
A
|
Males
| | | |
|
IDF MetS
| | | |
|
• Age
|
0.0102
|
0.1665
|
0.69 (0.65, 0.74)
|
|
• Intercept
|
−1.1411
|
0.0048
| |
|
ATPIII Mets
| | | |
|
• Age
|
0.0117
|
0.1897
|
0.72 (0.67, 0.77)
|
|
• Intercept
|
−1.2976
|
0.0089
| |
| |
Females **
| | | |
| |
IDF MetS
| | | |
|
• Age 30 yr
| | |
0.82 (0.71, 0.90)
|
|
• Age 50 yr
| |
<0.001
|
0.77 (0.68, 0.82)
|
|
• Age 70 yr
| | |
0.58 (0.48, 0.68)
|
| |
ATPIII MetS
| | | |
|
• Age 30 yr
| | |
0.83 (0.71, 0.91)
|
|
• Age 50 yr
| |
0.012
|
0.80 (0.71, 0.85)
|
|
• Age 70 yr
| | |
0.61 (0.52, 0.70)
|
|
B
|
Males
| | | |
|
IDF MetS
| | | |
|
• Age
|
−0.0113
|
0.8998
|
0.68 (0.59, 0.78)
|
|
• Intercept
|
0.1406
|
0.5160
| |
|
ATPIII MetS
| | | |
|
• Age
|
−0.0029
|
0.8595
|
0.72 (0.62, 0.81)
|
|
• Intercept
|
−0.4692
|
0.6515
| |
| |
Females
| | | |
| |
IDF MetS
| | | |
|
• Age
|
−0.0010
|
0.9656
|
0.54 (0.44, 0.64)
|
|
• Intercept
|
0.0173
|
0.9914
| |
| |
ATPIII MetS
| | | |
|
• Age
|
−0.0010
|
0.9656
|
0.54 (0.44, 0.64)
|
| |
• Intercept
|
0.0173
|
0.9914
| |
- Areas under the ROC curves for non-diabetic (A) and diabetic (B) adults (n = 2459).
- AUC (95% CI), area under the ROC curve (95% Confidence Interval). *ROC regression models incorporating age as covariate. **The AUC was estimated for three ages (30, 50, and 70 years) to illustrate the performance of HOMA-IR. HOMA-IR, homeostasis model assessment of IR; ATPIII, Third Adult Treatment Panel; IDF, International Diabetes Federation; MetS, Metabolic Syndrome.